TY - JOUR
T1 - No effects of a 6-week intervention with a glucagon-like peptide-1 receptor agonist on pancreatic volume and oedema in obese men without diabetes
AU - Svane, Maria S
AU - Johannesen, Helle H
AU - Martinussen, Christoffer
AU - Bojsen-Møller, Kirstine N
AU - Hansen, Martin Lundsgaard
AU - Hansen, Adam E
AU - Deacon, Carolyn F
AU - Hartmann, Bolette
AU - Keller, Sune H
AU - Klausen, Thomas L
AU - Loft, Annika
AU - Kjaer, Andreas
AU - Madsbad, Sten
AU - Löfgren, Johan
AU - Holst, Jens J
AU - Wewer Albrechtsen, Nicolai J
N1 - © 2020 John Wiley & Sons Ltd.
PY - 2020/10/1
Y1 - 2020/10/1
N2 - AIM: To investigate the effect of a glucagon-like peptide-1 receptor agonist (GLP-1RA), liraglutide, on pancreatic volume, oedema, cellularity and DNA synthesis in humans.MATERIALS AND METHODS: We performed an open-label study in 14 obese men (age 38 ± 11 years, body mass index 32 ± 4 kg/m
2 ) without diabetes. Subjects were examined at baseline, during titration (week 4) of liraglutide towards 3.0 mg/day, and 2 weeks after steady-state treatment (week 6) of a final dose of liraglutide. The primary endpoint was pancreatic volume determined by magnetic resonance imaging. Secondary endpoints included pancreatic oedema and cellularity, positron emission tomography-based [
18 F]fluorothymidine (FLT) uptake (DNA synthesis) and plasma pancreatic enzymes.
RESULTS: Plasma amylase (+7 U/L [95% confidence intervals 3-11], P < .01) and lipase (+19 U/L [7-30], P < .01) increased during liraglutide treatment. Pancreatic volume did not change from baseline to steady state of treatment (+0.2 cm
3 [-8-8], P = .96) and no change in pancreatic cellular infiltration was found (P = .22). During titration of liraglutide, FLT uptake in pancreatic tissue increased numerically (+0.08 [0.00-0.17], P = .0507).
CONCLUSIONS: Six weeks of treatment with liraglutide did not affect pancreatic volume, oedema or cellularity in obese men without diabetes.
AB - AIM: To investigate the effect of a glucagon-like peptide-1 receptor agonist (GLP-1RA), liraglutide, on pancreatic volume, oedema, cellularity and DNA synthesis in humans.MATERIALS AND METHODS: We performed an open-label study in 14 obese men (age 38 ± 11 years, body mass index 32 ± 4 kg/m
2 ) without diabetes. Subjects were examined at baseline, during titration (week 4) of liraglutide towards 3.0 mg/day, and 2 weeks after steady-state treatment (week 6) of a final dose of liraglutide. The primary endpoint was pancreatic volume determined by magnetic resonance imaging. Secondary endpoints included pancreatic oedema and cellularity, positron emission tomography-based [
18 F]fluorothymidine (FLT) uptake (DNA synthesis) and plasma pancreatic enzymes.
RESULTS: Plasma amylase (+7 U/L [95% confidence intervals 3-11], P < .01) and lipase (+19 U/L [7-30], P < .01) increased during liraglutide treatment. Pancreatic volume did not change from baseline to steady state of treatment (+0.2 cm
3 [-8-8], P = .96) and no change in pancreatic cellular infiltration was found (P = .22). During titration of liraglutide, FLT uptake in pancreatic tissue increased numerically (+0.08 [0.00-0.17], P = .0507).
CONCLUSIONS: Six weeks of treatment with liraglutide did not affect pancreatic volume, oedema or cellularity in obese men without diabetes.
KW - antiobesity drug clinical trial GLP-1 analogue
U2 - 10.1111/dom.14106
DO - 10.1111/dom.14106
M3 - Journal article
C2 - 32495988
SN - 1462-8902
VL - 22
SP - 1837
EP - 1846
JO - Diabetes, Obesity and Metabolism
JF - Diabetes, Obesity and Metabolism
IS - 10
ER -